Inari Medical Announces Late-Breaking CLOUT Registry Data Demonstrating Long-Term Benefits of Lytic-Free Single-Session Near ...
June 07 2021 - 8:00AM
Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device
company focused on developing products to treat and transform the
lives of patients suffering from venous diseases, today announced
strongly positive interim results of the first 250 deep vein
thrombosis (“DVT”) patients enrolled in the ClotTriever Outcomes
Registry (“CLOUT”). This latest data showed that ClotTriever
removed 100% of the blood clots in the majority of DVT patients
without the need for thrombolytic drugs in short single-session
procedures. The late-breaking data was presented virtually at NCVH
2021 by principal investigator, Robert Beasley, MD, an
interventional radiologist at Palm Vascular Center in Miami, FL.
“CLOUT has shown us that by getting between the vessel wall and
the thrombus, ClotTriever can remove all of the clot without any
injury to the vein or its valves, restoring normal blood flow and
valve function,” said Dr. Beasley. “For patients with acute,
subacute, and chronic clot, ClotTriever has offered long-term
relief from the pain associated with DVT and a return to normal
life, free from the debilitating symptoms of post-thrombotic
syndrome (“PTS”).” Use of thrombolytics was completely avoided in
all 250 patients across the 24 registry sites and median blood loss
was a modest 50ml with a short median thrombectomy procedure time
of 28 minutes.
CLOUT is the largest prospective registry ever undertaken of a
lytic-free mechanical thrombectomy treatment for DVT. “This latest
data readout from the CLOUT registry offers further validation of
the frontline role mechanical thrombectomy is playing at a growing
number of hospitals in the US and internationally,” said Bill
Hoffman, Inari’s Chief Executive Officer. “We remain committed to
the generation of meaningful data on the path towards definitive
studies designed to revolutionize VTE treatment with devices that
remove large clot volume from large vessels, while completely
eliminating lytics and their consequent cost, ICU stay, and
bleeding complications.”
About Inari Medical, Inc.Inari Medical, Inc. is
a medical device company focused on developing products to treat
and transform the lives of patients suffering from venous diseases.
Inari has developed two minimally invasive, novel catheter-based
mechanical thrombectomy devices that are designed to remove large
clots from large vessels and eliminate the need for thrombolytic
drugs. The company purpose-built its products for the specific
characteristics of the venous system and the treatment of the two
distinct manifestations of venous thromboembolism, or VTE: deep
vein thrombosis and pulmonary embolism. The ClotTriever system is
510(k)-cleared by FDA and CE Mark approved for the treatment of
deep vein thrombosis. The FlowTriever system is 510(k)-cleared by
FDA and CE Mark approved for the treatment of pulmonary embolism
and clot in transit in the right atrium.
Investor Contact:Westwicke PartnersCaroline
CornerPhone +1-415-202-5678 caroline.corner@westwicke.com
An infographic accompanying this announcement is available
at
https://www.globenewswire.com/NewsRoom/AttachmentNg/4cbf7906-f2c0-41cd-aea4-a6ffe08e2ea2
Inari Medical (NASDAQ:NARI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Inari Medical (NASDAQ:NARI)
Historical Stock Chart
From Apr 2023 to Apr 2024